Celldex Therapeutics Clinical Trial Data
Celldex reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria (CSU), meeting the primary and all key secondary endpoints. The data showed rapid and sustained efficacy through 24 weeks, including in patients refractory to omalizumab, with a favorable safety profile. The company plans to submit a Biologics License Application (BLA) to the FDA in 2027.
- Earnings call
- Sep 22, 2026, 8:00 AM ET
“The results from our two Phase 3 EMBARQ-CSU trials showed efficacy that is best-in-disease in CSU. We believe barzolvolimab is well-positioned to address large CSU populations of high unmet need—as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.”
Anthony Marucci, Co-Founder, President, and Chief Executive Officer at Celldex
“Barzolvolimab continued to show unprecedented complete response rates across the overall studies and demonstrated strong differentiation in patient populations underserved by existing therapies, including those with severe disease or angioedema, and those whose disease is refractory to omalizumab.”
Diane Young, MD, Senior Vice President and Chief Medical Officer of Celldex